Next Article in Journal
Construction of Recombinant Human GM-CSF and GM-CSF-ApoA-I Fusion Protein and Evaluation of Their Biological Activity
Next Article in Special Issue
Effects of the Hydroethanolic Extract of Lycopodium selago L. on Scopolamine-Induced Memory Deficits in Zebrafish
Previous Article in Journal
Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer
Previous Article in Special Issue
Sleep-Based Interventions in Alzheimer’s Disease: Promising Approaches from Prevention to Treatment along the Disease Trajectory
Review

Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease

1
Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland
2
Faculty of Health Sciences, High School of Economics, Law and Medical Sciences, 25-734 Kielce, Poland
*
Author to whom correspondence should be addressed.
Academic Editor: Giulia Sita
Pharmaceuticals 2021, 14(5), 458; https://doi.org/10.3390/ph14050458
Received: 7 April 2021 / Revised: 7 May 2021 / Accepted: 10 May 2021 / Published: 13 May 2021
(This article belongs to the Special Issue Treatment of Alzheimer Disease)
Alzheimer’s disease (AD; progressive neurodegenerative disorder) is associated with cognitive and functional impairment with accompanying neuropsychiatric symptoms. The available pharmacological treatment is of a symptomatic nature and, as such, it does not modify the cause of AD. The currently used drugs to enhance cognition include an N-methyl-d-aspartate receptor antagonist (memantine) and cholinesterase inhibitors. The PUBMED, Medical Subject Heading and Clinical Trials databases were used for searching relevant data. Novel treatments are focused on already approved drugs for other conditions and also searching for innovative drugs encompassing investigational compounds. Among the approved drugs, we investigated, are intranasal insulin (and other antidiabetic drugs: liraglitude, pioglitazone and metformin), bexarotene (an anti-cancer drug and a retinoid X receptor agonist) or antidepressant drugs (citalopram, escitalopram, sertraline, mirtazapine). The latter, especially when combined with antipsychotics (for instance quetiapine or risperidone), were shown to reduce neuropsychiatric symptoms in AD patients. The former enhanced cognition. Procognitive effects may be also expected with dietary antioxidative and anti-inflammatory supplements—curcumin, myricetin, and resveratrol. Considering a close relationship between brain ischemia and AD, they may also reduce post-brain ischemia neurodegeneration. An investigational compound, CN-105 (a lipoprotein E agonist), has a very good profile in AD preclinical studies, and its clinical trial for postoperative dementia is starting soon. View Full-Text
Keywords: Alzheimer’s disease; antidepressants; antidiabetics; bexarotene; cognitive; curcumin; myricetin; resveratrol Alzheimer’s disease; antidepressants; antidiabetics; bexarotene; cognitive; curcumin; myricetin; resveratrol
MDPI and ACS Style

Miziak, B.; Błaszczyk, B.; Czuczwar, S.J. Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease. Pharmaceuticals 2021, 14, 458. https://doi.org/10.3390/ph14050458

AMA Style

Miziak B, Błaszczyk B, Czuczwar SJ. Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease. Pharmaceuticals. 2021; 14(5):458. https://doi.org/10.3390/ph14050458

Chicago/Turabian Style

Miziak, Barbara, Barbara Błaszczyk, and Stanisław J. Czuczwar 2021. "Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease" Pharmaceuticals 14, no. 5: 458. https://doi.org/10.3390/ph14050458

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop